Examine the complementary effects of omega lipid on lipid profile serum and compare it with effect of placebo of omega in patients With Chronic dialysis.
Not Applicable
- Conditions
- End stage renal disease.Chronic kidney disease
- Registration Number
- IRCT2014112520087N1
- Lead Sponsor
- Vice Chanceller for research of Ardabil University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients that have been receive dialysis therapy for more than three months? patients that have been received no anti-lipid drugs as yet.
Exclusion criteria for the study: Patients that can’t tolerate drugs receive? patients not interested in drugs receive? patients die during intervention.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method High Density Lipoprotein (HDL). Timepoint: Before and three months after intervention. Method of measurement: Laboratory measurement of serum HDL concentrations in scale mili mol / lit.;Low Density Lipoprotein (lDL). Timepoint: Before and three months after intervention. Method of measurement: Laboratory measurement of serum LDL concentrations in scale mili mol / lit.;Triglyceride(TG). Timepoint: Before and three months after intervention. Method of measurement: Laboratory measurement of serum TG concentrations in scale mili mol / lit.
- Secondary Outcome Measures
Name Time Method Cross Reacting Protein (CRP). Timepoint: Before intervention, three months after intervention. Method of measurement: Laboratory measurement of serum CRP concentrations in scale Mg / dl.